Table 2.
Treatment characteristics
| Total cohort (N = 100) | Pneumonitis (N = 13) | |
|---|---|---|
| Tumour site | ||
| Right breast | 45 | 5 |
| Left breast | 55 | 8 |
| Treatment postsurgery | ||
| RT alone | S | 2 |
| RT + systemic therapy | 92 | 11 |
| Radiotherapy | ||
| RT BCW | 75 | 5 |
| RT BCW + S | 8 | 1 |
| RT BCW + S + P | 17 | 7* (p < 0.005) |
| RT fields + systemic therapies | ||
| 2FRT | ||
| RT alone BCW | 6 | 0 |
| RT BCW + CTX | 4 | 0 |
| RT BCW + H | 57 | 5 |
| RT BCW + CTX + Ab | 3 | 0 |
| RT BCW + CTX + H | 2 | 0 |
| RT BCW + CTX + Ab + H | 3 | 0 |
| 3FRT | ||
| RT alone BCW + S | 1 | 1 |
| RT BCW + S + CTX | 2 | 0 |
| RT BCW + S + H | 3 | 0 |
| RT BCW + S + CTX + H | 2 | 0 |
| 4FRT | ||
| RT alone BCW + S + P | 1 | 1 |
| RT BCW + S + P + CTX | 1 | 0 |
| RT BCW + S + P + H | 4 | 1 |
| RT BCW + S + P + CTX + Ab | 1 | 0 |
| RT BCW + S + P + CTX + H | 7 | 2 |
| RT BCW + S + P + CTX + Ab + H | 3 | 3* (p < 0.001) |
| Systemic therapies | ||
| Chemotherapy | ||
| TEC | 1 | 1 |
| FEC | 3 | 1 |
| FEC + docetaxel (PACS 01) | 9 | 0 |
| EC + docetaxel | 7 | 1 |
| Doxorubicin + docetaxel | 4 | 2 |
| Carboplatinum + paclitaxel | 4 | 0 |
| Antibodies | ||
| Trastuzumab | 5 | 0 |
| Trastuzumab + pertuzumab | 3 | 2 |
| Anti-hormonal therapy | ||
| Aromatase inhibitors | 46 | 6 |
| Aromatase inhibitors + goserelin | 3 | 0 |
| Tamoxifen | 6 | 0 |
| Tamoxifen + goserelin | 24 | 5* (p < 0.04) |
| Vaccines | ||
| Tecemotide (MUC1; Stimuvax) | 2 | 1 |
RT radiotherapy, BCW breast and chest wall, S supraclavicular region, P parasternal region, CTX chemotherapy, Ab antibodies, H anti-hormonal therapy, EC epirubicin, cyclophosphamide, FEC 5-fluorouracil, epirubicin and cyclophosphamide, TEC docetaxel, epirubicin, cyclophosphamide, MUC1 a vaccine of MUC1 type
* statistically siginficant